Trade Report: The Aratana Therapeutics Inc. (PETX) Insider Sold $100,000.00 in Stock

The Aratana Therapeutics Inc. (PETX) Insider Sold $100,000.00 in Stock

Aratana Therapeutics Inc. (NASDAQ:PETX) insider Ernst Heinen sold 10,000 shares of the stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $10.00, for a total transaction of $100,000.00. Following the completion of the transaction, the insider now owns 115,494 shares in the company, valued at $1,154,940. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Aratana Therapeutics Inc. (NASDAQ:PETX) opened at 9.36 on Monday. The company’s 50 day moving average price is $9.27 and its 200 day moving average price is $7.35. Aratana Therapeutics Inc. has a one year low of $2.56 and a one year high of $10.73. The firm’s market capitalization is $331.48 million.

Aratana Therapeutics (NASDAQ:PETX) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.37. Aratana Therapeutics had a negative return on equity of 17.53% and a negative net margin of 166.67%. The company had revenue of $38.05 million for the quarter, compared to analyst estimates of $15.14 million. During the same period in the prior year, the company posted ($0.23) EPS. On average, analysts expect that Aratana Therapeutics Inc. will post ($0.78) EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. BlackRock Advisors LLC raised its position in shares of Aratana Therapeutics by 3.6% in the second quarter. BlackRock Advisors LLC now owns 15,915 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 547 shares during the last quarter. American International Group Inc. raised its position in shares of Aratana Therapeutics by 10.6% in the second quarter. American International Group Inc. now owns 19,201 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 1,841 shares during the last quarter. Metropolitan Life Insurance Co. NY acquired a new position in shares of Aratana Therapeutics during the second quarter worth about $162,000. Parametric Portfolio Associates LLC raised its position in shares of Aratana Therapeutics by 16.6% in the second quarter. Parametric Portfolio Associates LLC now owns 27,958 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 3,989 shares during the last quarter. Finally, Baird Financial Group Inc. acquired a new position in shares of Aratana Therapeutics during the second quarter worth about $198,000. 85.56% of the stock is currently owned by institutional investors.

Several equities analysts have commented on the stock. Barclays PLC dropped their price target on shares of Aratana Therapeutics from $15.00 to $11.00 and set an “overweight” rating on the stock in a research note on Thursday, August 11th. Credit Suisse Group AG restated a “buy” rating and set a $11.00 target price on shares of Aratana Therapeutics in a research report on Wednesday, August 10th. Jefferies Group began coverage on shares of Aratana Therapeutics in a research report on Friday, August 19th. They set a “buy” rating and a $13.00 target price on the stock. William Blair restated an “outperform” rating on shares of Aratana Therapeutics in a research report on Wednesday, August 17th. Finally, Lake Street Capital restated a “buy” rating and set a $15.00 target price on shares of Aratana Therapeutics in a research report on Tuesday, September 6th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $11.28.

Aratana Therapeutics Company Profile

Related posts

Leave a Comment